Skip to content
10-Q

Quarterly Report

ONYX PHARMACEUTICALS INC

0001104659-13-038892

← back to feed
Filed
May 8, 2013 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2013 · May 3, 2013 72.74M sh
Shares Diluted Q1 2013 · Mar 31, 2013 71.09M sh
Shares Diluted Q1 2013 · Mar 31, 2012 63.7M sh
Stock Repurchased Q1 2013 · Mar 31, 2013 $417K
Stock Repurchased Q1 2013 · Mar 31, 2012 $124K
Capex Q1 2013 · Mar 31, 2013 $6.09M
Capex Q1 2013 · Mar 31, 2012 $8.88M
Cash And Equivalents Q1 2013 · Mar 31, 2013 $436.52M
Cash And Equivalents Q1 2013 · Dec 31, 2012 $153.24M
Cash And Equivalents Q1 2013 · Mar 31, 2012 $133.02M
Cash And Equivalents Q1 2013 · Dec 31, 2011 $171.55M
Stockholders Equity Q1 2013 · Mar 31, 2013 $1.16B
Stockholders Equity Q1 2013 · Dec 31, 2012 $820.12M
Current Liabilities Q1 2013 · Mar 31, 2013 $113.14M
Current Liabilities Q1 2013 · Dec 31, 2012 $131.37M
Current Assets Q1 2013 · Mar 31, 2013 $1.02B
Current Assets Q1 2013 · Dec 31, 2012 $687.96M
Total Assets Q1 2013 · Mar 31, 2013 $1.68B
Total Assets Q1 2013 · Dec 31, 2012 $1.35B
Eps Diluted Q1 2013 · Mar 31, 2013 −$0.47
Eps Diluted Q1 2013 · Mar 31, 2012 −$0.88
Eps Basic Q1 2013 · Mar 31, 2013 −$0.47
Eps Basic Q1 2013 · Mar 31, 2012 −$0.88
Sga Expense Q1 2013 · Mar 31, 2013 $72.55M
Sga Expense Q1 2013 · Mar 31, 2012 $38.94M
Net Income Q1 2013 · Mar 31, 2013 −$33.67M
Net Income Q1 2013 · Mar 31, 2012 −$56.21M
Operating Income Q1 2013 · Mar 31, 2013 −$28.47M
Operating Income Q1 2013 · Mar 31, 2012 −$50.75M
Cost Of Revenue Q1 2013 · Mar 31, 2013 $1.97M
Revenue Q1 2013 · Mar 31, 2013 $145.49M
Revenue Q1 2013 · Mar 31, 2012 $72.03M